Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

CattleFarmerJ Mar. 21 at 8:29 PM

$CABA I was just on MorganStanely and they have them reporting the 31 but the Nasdaq has the 30th so idk what's going on im sure it will be officially set this week.

1 · Reply

Rumenigge Mar. 21 at 8:07 AM

$CABA FOR THE 30TH CALL YOU EXPECT, IN YOUR OPINION THERE COULD BE SOME NEWS OR SENSATIONAL NEWS, GIVEN THAT THE ANALYSTS' TARGET PRICES ARE NOW ALREADY A YEAR AWAY AND ARE USUALLY NO MORE THAN 12 MONTHS

1 · Reply

gata2016 Mar. 20 at 2:32 PM

$CABA Bought more. Continuing to accumulate

0 · Reply

christopher18 Mar. 20 at 2:09 PM

$CABA I'm long but there is no way that this stock holds any gains from the upcoming earnings report. This is just too volatile, and data will be two months out.

2 · Reply

Bronco6970 Mar. 20 at 1:45 PM

$CABA I can’t find an official post anywhere, but as I mentioned before, historically, earnings should be released by the end of the month. Probably sometime between the 24th and 31st of this month. 🚀

1 · Reply

robbied61 Mar. 20 at 1:02 PM

$CABA hey bronco do u have any guess were and when data

0 · Reply

Bronco6970 Mar. 20 at 1:00 PM

$CABA it’s amazing, stock prices crumbling all around us, yet Caba stays on course. Data around the corner, love my Caba!

0 · Reply

robbied61 Mar. 20 at 12:45 PM

$CABA just stay the course data soon will complete ly cha nge this mkt cap and its value 👌

0 · Reply

texmade2 Mar. 20 at 11:28 AM

$CABA I think we moving up soon.

0 · Reply

DragonAlgo Mar. 20 at 8:34 AM

🐉 $CABA CALL — DragonAlgo® Signal Contract: CABA CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 🔗 https://dragonalgo.com

0 · Reply

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 5, 2026, 8:00 AM EST - 6 weeks ago

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 27, 2026, 11:01 AM EST - 7 weeks ago

Cabaletta Bio: Do You Buy With The Insiders?

Jan 12, 2026, 8:00 AM EST - 2 months ago

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 2 months ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Dec 3, 2025, 5:23 PM EST - 3 months ago

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:30 AM EST - 4 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 8:00 AM EST - 4 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 5 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 7, 2025, 6:20 AM EDT - 5 months ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 8 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 8 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 10 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 10 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 10 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 10 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 10 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 11 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 1 year ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 1 year ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 1 year ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 2 years ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

CattleFarmerJ Mar. 21 at 8:29 PM

$CABA I was just on MorganStanely and they have them reporting the 31 but the Nasdaq has the 30th so idk what's going on im sure it will be officially set this week.

1 · Reply

Rumenigge Mar. 21 at 8:07 AM

1 · Reply

gata2016 Mar. 20 at 2:32 PM

$CABA Bought more. Continuing to accumulate

0 · Reply

christopher18 Mar. 20 at 2:09 PM

$CABA I'm long but there is no way that this stock holds any gains from the upcoming earnings report. This is just too volatile, and data will be two months out.

2 · Reply

Bronco6970 Mar. 20 at 1:45 PM

1 · Reply

robbied61 Mar. 20 at 1:02 PM

$CABA hey bronco do u have any guess were and when data

0 · Reply

Bronco6970 Mar. 20 at 1:00 PM

$CABA it’s amazing, stock prices crumbling all around us, yet Caba stays on course. Data around the corner, love my Caba!

0 · Reply

robbied61 Mar. 20 at 12:45 PM

$CABA just stay the course data soon will complete ly cha nge this mkt cap and its value 👌

0 · Reply

texmade2 Mar. 20 at 11:28 AM

$CABA I think we moving up soon.

0 · Reply

DragonAlgo Mar. 20 at 8:34 AM

0 · Reply

Moonman321 Mar. 19 at 10:02 PM

$CABA look at the RUT Small cap rotation still in effect and has been for months Good macro news incoming this will blow past 370

0 · Reply

robbied61 Mar. 19 at 6:24 PM

$CABA we are in agoid spot great technology that works in aspace that is paying premium for this type of platform

0 · Reply

Achandler787 Mar. 19 at 1:56 PM

$CABA cmon back CABA!!!

0 · Reply

D541 Mar. 18 at 8:30 PM

$CABA I am ready to move if you are !

0 · Reply

Blaze321 Mar. 18 at 8:19 PM

$CABA Something is up for that size block sale trade this morning. Sucks how retail traders get F'ed !

1 · Reply

Moonman321 Mar. 18 at 6:34 PM

$CABA “‘Trash stock’ 😂…translation: you got caught short and now you’re coping in the comments. If it was such an easy short, you’d be posting your position—not spamming ‘trash’ like that means anything. I’ll stick with the data and the setup while you try to talk it down from the sidelines.”😆

2 · Reply

Moonman321 Mar. 18 at 6:27 PM

$CABA who got shook out lol Think macro not the volume of the noise 👻 This is still a gift right here !! grab it while you can 💥

0 · Reply

Achandler787 Mar. 18 at 3:07 PM

$CABA earnings and Business updates in 12 days - shorts likely to take this gift and cover- plus some optimism = move upside a strong possibility

0 · Reply

CRKissel Mar. 18 at 2:41 PM

$CABA Added! Share goal hit! Let’s start stacking that good news!

0 · Reply

SignoreRossi Mar. 18 at 2:40 PM

$CABA great opportunity, loaded another 15k shares.

0 · Reply

Moonman321 Mar. 18 at 2:33 PM

$CABA suck it up right here What a 🎁

0 · Reply

Moonman321 Mar. 18 at 2:30 PM

$CABA hold!! 💪🏻

0 · Reply

Market Cap	285.91M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,738,500
Avg Vol	3,242,726
Day's Range	N/A - N/A
Shares Out	96.27M
Stochastic %K	14%
Beta	3.25
Analysts	Strong Sell
Price Target	$13.12